Anastasia-Stefania Alexopoulos1,2, Ali Qamar3,4, Kathryn Hutchins3,4, Matthew J Crowley3,4, Bryan C Batch3,4, John R Guyton3. 1. Department of Medicine, Division of Endocrinology, Duke University Medical Center, Durham, NC, USA. asa61@duke.edu. 2. Department of Medicine, Division of Endocrinology, Durham VA Medical Center, Durham, NC, USA. asa61@duke.edu. 3. Department of Medicine, Division of Endocrinology, Duke University Medical Center, Durham, NC, USA. 4. Department of Medicine, Division of Endocrinology, Durham VA Medical Center, Durham, NC, USA.
Abstract
PURPOSE OF REVIEW: Moderate hypertriglyceridemia is exceedingly common in diabetes, and there is growing evidence that it contributes to residual cardiovascular risk in statin-optimized patients. Major fibrate trials yielded inconclusive results regarding the cardiovascular benefit of lowering triglycerides, although there was a signal for improvement among patients with high triglycerides and low high-density lipoprotein (HDL)-the "diabetic dyslipidemia" phenotype. Until recently, no trials have examined a priori the impact of triglyceride lowering in patients with diabetic dyslipidemia, who are likely among the highest cardiovascular-risk patients. RECENT FINDINGS: In the recent REDUCE IT trial, omega-3 fatty acid icosapent ethyl demonstrated efficacy in lowering cardiovascular events in patients with high triglycerides, low HDL, and statin-optimized low-density lipoprotein (LDL). The ongoing PROMINENT trial is examining the impact of pemafibrate in a similar patient population. Emerging evidence suggests that lowering triglycerides may reduce residual cardiovascular risk, especially in high-risk patients with diabetic dyslipidemia.
PURPOSE OF REVIEW: Moderate hypertriglyceridemia is exceedingly common in diabetes, and there is growing evidence that it contributes to residual cardiovascular risk in statin-optimized patients. Major fibrate trials yielded inconclusive results regarding the cardiovascular benefit of lowering triglycerides, although there was a signal for improvement among patients with high triglycerides and low high-density lipoprotein (HDL)-the "diabetic dyslipidemia" phenotype. Until recently, no trials have examined a priori the impact of triglyceride lowering in patients with diabetic dyslipidemia, who are likely among the highest cardiovascular-risk patients. RECENT FINDINGS: In the recent REDUCE IT trial, omega-3 fatty acidicosapent ethyl demonstrated efficacy in lowering cardiovascular events in patients with high triglycerides, low HDL, and statin-optimized low-density lipoprotein (LDL). The ongoing PROMINENT trial is examining the impact of pemafibrate in a similar patient population. Emerging evidence suggests that lowering triglycerides may reduce residual cardiovascular risk, especially in high-risk patients with diabetic dyslipidemia.
Entities:
Keywords:
Diabetic dyslipidemia; Hypertriglyceridemia; Medications; Type 2 diabetes
Authors: Andres Digenio; Richard L Dunbar; Veronica J Alexander; Marcus Hompesch; Linda Morrow; Richard G Lee; Mark J Graham; Steven G Hughes; Rosie Yu; Walter Singleton; Brenda F Baker; Sanjay Bhanot; Rosanne M Crooke Journal: Diabetes Care Date: 2016-06-06 Impact factor: 19.112
Authors: John J P Kastelein; Kevin C Maki; Andrey Susekov; Marat Ezhov; Borge G Nordestgaard; Ben N Machielse; Douglas Kling; Michael H Davidson Journal: J Clin Lipidol Date: 2013-10-14 Impact factor: 4.766
Authors: Terry A Jacobson; Matthew K Ito; Kevin C Maki; Carl E Orringer; Harold E Bays; Peter H Jones; James M McKenney; Scott M Grundy; Edward A Gill; Robert A Wild; Don P Wilson; W Virgil Brown Journal: J Clin Lipidol Date: 2015-04-07 Impact factor: 4.766
Authors: Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef Journal: J Clin Endocrinol Metab Date: 2012-09 Impact factor: 5.958
Authors: Peter Willeit; Paul M Ridker; Paul J Nestel; John Simes; Andrew M Tonkin; Terje R Pedersen; Gregory G Schwartz; Anders G Olsson; Helen M Colhoun; Florian Kronenberg; Christiane Drechsler; Christoph Wanner; Samia Mora; Anastasia Lesogor; Sotirios Tsimikas Journal: Lancet Date: 2018-10-04 Impact factor: 79.321
Authors: Martin J Landray; Richard Haynes; Jemma C Hopewell; Sarah Parish; Theingi Aung; Joseph Tomson; Karl Wallendszus; Martin Craig; Lixin Jiang; Rory Collins; Jane Armitage Journal: N Engl J Med Date: 2014-07-17 Impact factor: 91.245